



Impact Analyses: Baxter, North Carolina

October 14, 2024

Tornado disrupts manufacturing activity at Baxter's North Carolina facility

Baxter's IV fluid plant at North Carolina (65 Pitts Station Rd, Marion, North Carolina) was damaged by a severe tornado last month and as a result manufacturing operations are shut down. While Baxter has already started the restoration and rebuilding of the facility, but the resolution timeline is not clear.

This facility holds great significance not just for Baxter, but for the entire US market. This is because, USFDA issued warning that disruption at the facility can create nationwide shortage of certain products. As per our records,

1. Total of 46 drugs (44 NDAs and 2 ANDAs) are being manufactured in this facility.
2. Out of the 44 NDAs, 33 products face no generic competition and another 8 products have only one generic competitor
3. ■ out of 46 products are backed by other facilities.
4. This facility contributes ~60% of Baxter's total US sales.
5. Fresenius Kabi is likely to be the biggest beneficiary if disruption happened.



Impact Analyses: Baxter, North Carolina

Table 1
LOW COMPETITION PRODUCTS

Sr. No.	Appl. No	Generic Name	Brand Name	Appl. Owner	Other Gx competitors	Other Facility for same NDA/ANDA	Complexity	Sales CY23 (IN USD MN)
1	NDA 013684	OSMITROL 10% IN WATER IN PLASTIC CONTAINER	MANNITOL	BAXTER HLTHCARE				0.11
2	Premium Content							
3								
4								
5								
6								
7								
8								
9								
10								
11								
12								



Impact Analyses: Baxter, North Carolina

Sr. No.	Appl. No	Generic Name	Brand Name	Appl. Owner	Other Gx competitors	Other Facility for same NDA/ANDA	Complexity	Sales CY23 (IN USD MN)
13								
14								
15								
16								
17								
18								
19								
20								
21								
22								
23								
24								

Premium Content



Impact Analyses: Baxter, North Carolina

Sr. No.	Appl. No	Generic Name	Brand Name	Appl. Owner	Other Gx competitors	Other Facility for same NDA/ANDA	Complexity	Sales CY23 (IN USD MN)
25								
26								
27								
28								
29								
30								
31								
32								
33								
34								

Premium Content



Impact Analyses: Baxter, North Carolina

Sr. No.	Appl. No	Generic Name	Brand Name	Appl. Owner	Other Gx competitors	Other Facility for same NDA/ANDA	Complexity	Sales CY23 (IN USD MN)
35								
36								
37								
38								
39								
40								
41								
42								

Premium Content



Impact Analyses: Baxter, North Carolina

Sr. No.	Appl. No	Generic Name	Brand Name	Appl. Owner	Other Gx competitors	Other Facility for same NDA/ANDA	Complexity	Sales CY23 (IN USD MN)
43	Premium Content							
44								
Total								

* Cos highlighted in red are Indian listed companies

Source:- GenUS, Research Delta Advisors

Note: Sales as per Medicaid Drug Rebate Program



Impact Analyses: Baxter, North Carolina

**Table 2
COMMODITIZED PRODUCTS**

Sr No.	AppNo	Generic Name	Brand Name	Appl. Owner	Other Gx competitors	Other Facility for same NDA/ANDA	Sales CY23 (IN USD MN)
1	Premium Content						
2							
Total							

Source:- GenUS, Research Delta Advisors

Note: Sales as per Medicaid Drug Rebate Program